Published in Cancer Weekly, October 5th, 2004
"Fanconi anemia (FA) is a rare genetic disorder characterized by bone-marrow failure and cellular hypersensitivity to crosslinking agents, including cisplatin. Here, we studied the use of the FA pathway as a possible target for cancer gene therapy with the aim to sensitize tumor cells for cisplatin by interfering with the FA pathway," investigators in the Netherlands stated.
"As proof-of-principle, FA and non-FA lymphoblast-derived tumors were grown subcutaneously in SCID mice and treated with two different concentrations of cisplatin," described M. Ferrer and colleagues, VU...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.